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Abstract 
The proper use and interpretation of ?forced 
degradation? experiments - performed during 
the early development stages of a drug project 
- allows analysts to identify quickly problems 
that may occur later. Here we report an 
example where fo rced degrada t ion 
experiments allowed the rapid identification 
of a deleterious degradation mechanism 
occurring unexpectedly in a pharmaceutical 
formulation 
Introduction	

Non- recep to r t y ros ine k inase s a r e 
cytoplasmic proteins located on membranes 
within the cell. The Src and Abl non-receptor 
tyrosine kinases are involved in cell growth 
and differentiation and are over-expressed in 
some tumor cells. AZD0424 (Fig. 1) was 
originally discovered by AstraZeneca. It is a 
dual selective inhibitor of Src and Abl non-
receptor tyrosine kinases which is being 
developed for Phase I clinical trial through 
the Cance r Resea rch UK Cl in i ca l 
Development Par tnership in i t ia t ive . 
F o r m u l a t i o n , p r e - f o r m u l a t i o n a n d 
development studies were performed at the 
Cancer Research UK Formulation Unit, 
University of Strathclyde. The proposed 
formulation was a polyethylene glycol (PEG) 
based melt fill capsule.  
 
Materials and Methods 
AZD0424 analysis was performed on Thermo 
Surveyor and Accela HPLC systems with 
PDA and/or Thermo LCQ Deca XP Max MS 
(ion trap) detection (Thermo, Hemel 
Hempstead, UK). HPLC analysis was 
performed using a Synergi Polar RP80 4µm, 
150 x 4.6 mm id column (Phenomenex, 
Macclesfield, UK) with the gradient specified 
in Table 1. Flowrate was 1 ml/min, injection 
volume was 25µl, column temperature set to 
45˚C and detection wavelength at 314 nm. 
 
AZD0424 oxidative stress samples were by 
incubation of the drug in a 0.2% solution of 
H2O2 at 25˚C overnight. Formulated 
AZD0424 samples were generated using 1% 
AZD0424 in PEG heated to 55˚C. 
 
Results  
Upon closer inspection of the HPLC traces 
from AZD0424/PEG capsules incubated in an 
ICH compliant stability study [1], the 
retention time of the main degradant was 
found to coincide with the main degradant 
observed during the earlier oxidative stress 
degradation experiments (see Fig. 2).  
Results (continued) 
Armed with this information, degraded 
samples of AZD0424 were assayed by LCMS 
leading to a proposed degradant structure 
(Fig. 3). In addition a review of the literature 
a ff i rmed the presence of peroxide 
contaminants in PEGs [2]. 
 
Conclusion 
In the authors’ lab we perform physico-
chemical characterisation of putative drug 
compounds as part of the pre-formulation and 
analytical method development: working on 
the premise that understanding a molecule’s 
properties is key to analysing, formulating 
and successfully manufacturing a drug 
product. This can a time consuming and 
labour intensive phase of the project, 
requiring the attention of experienced and 
qualified staff.  
 
However, establishing an understanding of 
AZD0424 degradation early in the project 
was a key part of establishing the mechanism 
for a the deleterious degradation of AZD0424 
found at the stability/pre-clinical drug 
development stage. A mechanism for the 
degradation was postulated with a few hours, 
confirmed by experiments within a week, and 
the project set back on track with the 
purchase of ‘low-peroxide’ PEGs.  
 
The authors believe that a firm foundation of 
chemical and physico-chemical knowledge is 
key to effective progression of a clinical drug 
project. In the case we have presented here, 
the work allowed the development team to 
move rapidly onto other formulations that 
would mitigate the degradation thus allowing 
the project to proceed in a timeous manner.  
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Time  0.3% formic 
acid:water 
Methanol 
0 min 65% 35% 
30 min 15% 85% 
30.1 min 65% 35% 
40 min 65% 85% 
Figure 1: Structure of 
AZD0424	

Figure 2  Effect of time and temperature 
on main degradant concentration	

Table 1  HPLC mobile phase 
conditions 
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Level of oxidized impurity (% pa) v's incubation 
time (days) at different temperatures.
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Figure 3: Structure of 
AZD0424 oxided degradant	

 
